Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0MG2R
|
|||
| Former ID |
DIB005803
|
|||
| Drug Name |
ALX-0141
|
|||
| Synonyms |
Nanobody therapeutic (bone disease), Ablynx; Nanobody therapeutic (osteoporosis), Ablynx
Click to Show/Hide
|
|||
| Indication | Osteoporosis [ICD-11: FB83.0; ICD-10: M85.8] | Phase 1 | [1] | |
| Company |
Ablynx NV
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Osteoclast differentiation factor (ODF) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| NF-kappa B signaling pathway | ||||
| Osteoclast differentiation | ||||
| Prolactin signaling pathway | ||||
| Rheumatoid arthritis | ||||
| NetPath Pathway | Leptin Signaling Pathway | |||
| TWEAK Signaling Pathway | ||||
| Pathway Interaction Database | IL6-mediated signaling events | |||
| Reactome | TNFR2 non-canonical NF-kB pathway | |||
| TNFs bind their physiological receptors | ||||
| TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway | ||||
| WikiPathways | Osteoblast Signaling | |||
| Vitamin D Receptor Pathway | ||||
| Differentiation Pathway | ||||
| RANKL/RANK Signaling Pathway | ||||
| Osteoclast Signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031383) | |||
| REF 2 | Clinical pipeline report, company report or official report of Ablynx. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.